Cargando…
Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs)
Occupational exposure of anticancer agents during their preparation has been recognized as a serious hazard. Closed system drug transfer devices (CSTDs) enable “safe” preparation of agents for medical personnel and ensure a safe hospital environment. However, artificial particles of infusion materia...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741972/ https://www.ncbi.nlm.nih.gov/pubmed/34996936 http://dx.doi.org/10.1038/s41598-021-03780-0 |
_version_ | 1784629609620307968 |
---|---|
author | Sumikawa, Satomi Yakushijin, Yoshihiro Aogi, Kenjiro Yano, Takuya Hiroki Hashimoto Tsukui, Chiyuki Noguchi, Tadashi Shiraishi, Taro Horikawa, Yasuhiro Yasuoka, Yasuo Tanaka, Akihiro Hidaka, Noriaki Tanaka, Mamoru |
author_facet | Sumikawa, Satomi Yakushijin, Yoshihiro Aogi, Kenjiro Yano, Takuya Hiroki Hashimoto Tsukui, Chiyuki Noguchi, Tadashi Shiraishi, Taro Horikawa, Yasuhiro Yasuoka, Yasuo Tanaka, Akihiro Hidaka, Noriaki Tanaka, Mamoru |
author_sort | Sumikawa, Satomi |
collection | PubMed |
description | Occupational exposure of anticancer agents during their preparation has been recognized as a serious hazard. Closed system drug transfer devices (CSTDs) enable “safe” preparation of agents for medical personnel and ensure a safe hospital environment. However, artificial particles of infusion materials have been reported during CSTD use. Here, the incidence of insoluble fine particles during preparation of anticancer agents using CSTDs was examined. Visible insoluble fine particles were found in 465 (9.4%) of 4948 treatment cases at Ehime University Hospital with CSTD use. Contaminants occurred more frequently during preparation of monoclonal antibodies than cytotoxic anticancer agents (19.4% vs. 4.1%, respectively, P < 0.01). A similar survey was conducted at nine hospitals to investigate the incidence of insoluble fine particles with or without CSTDs. Insoluble fine particles were detected in 113 (15.4%) of 732 treatment cases during preparation of monoclonal antibodies with CSTD use. In contrast, the occurrence of insoluble fine particles without CSTDs was found in only 3 (0.073%) of 4113 treatment cases. Contamination with CSTDs might cause harmful effects on patients during cancer therapy. We strongly recommend the use of in-line filters combined with infusion routes after CSTD use to avoid contamination-associated adverse events. |
format | Online Article Text |
id | pubmed-8741972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87419722022-01-10 Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) Sumikawa, Satomi Yakushijin, Yoshihiro Aogi, Kenjiro Yano, Takuya Hiroki Hashimoto Tsukui, Chiyuki Noguchi, Tadashi Shiraishi, Taro Horikawa, Yasuhiro Yasuoka, Yasuo Tanaka, Akihiro Hidaka, Noriaki Tanaka, Mamoru Sci Rep Article Occupational exposure of anticancer agents during their preparation has been recognized as a serious hazard. Closed system drug transfer devices (CSTDs) enable “safe” preparation of agents for medical personnel and ensure a safe hospital environment. However, artificial particles of infusion materials have been reported during CSTD use. Here, the incidence of insoluble fine particles during preparation of anticancer agents using CSTDs was examined. Visible insoluble fine particles were found in 465 (9.4%) of 4948 treatment cases at Ehime University Hospital with CSTD use. Contaminants occurred more frequently during preparation of monoclonal antibodies than cytotoxic anticancer agents (19.4% vs. 4.1%, respectively, P < 0.01). A similar survey was conducted at nine hospitals to investigate the incidence of insoluble fine particles with or without CSTDs. Insoluble fine particles were detected in 113 (15.4%) of 732 treatment cases during preparation of monoclonal antibodies with CSTD use. In contrast, the occurrence of insoluble fine particles without CSTDs was found in only 3 (0.073%) of 4113 treatment cases. Contamination with CSTDs might cause harmful effects on patients during cancer therapy. We strongly recommend the use of in-line filters combined with infusion routes after CSTD use to avoid contamination-associated adverse events. Nature Publishing Group UK 2022-01-07 /pmc/articles/PMC8741972/ /pubmed/34996936 http://dx.doi.org/10.1038/s41598-021-03780-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Sumikawa, Satomi Yakushijin, Yoshihiro Aogi, Kenjiro Yano, Takuya Hiroki Hashimoto Tsukui, Chiyuki Noguchi, Tadashi Shiraishi, Taro Horikawa, Yasuhiro Yasuoka, Yasuo Tanaka, Akihiro Hidaka, Noriaki Tanaka, Mamoru Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) |
title | Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) |
title_full | Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) |
title_fullStr | Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) |
title_full_unstemmed | Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) |
title_short | Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs) |
title_sort | frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (cstds) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741972/ https://www.ncbi.nlm.nih.gov/pubmed/34996936 http://dx.doi.org/10.1038/s41598-021-03780-0 |
work_keys_str_mv | AT sumikawasatomi frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT yakushijinyoshihiro frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT aogikenjiro frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT yanotakuya frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT hiroki frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT hashimoto frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT tsukuichiyuki frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT noguchitadashi frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT shiraishitaro frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT horikawayasuhiro frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT yasuokayasuo frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT tanakaakihiro frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT hidakanoriaki frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds AT tanakamamoru frequencyandcomponentanalysisofcontaminantsgeneratedinpreparationofanticanceragentsusingclosedsystemdrugtransferdevicescstds |